Extrastriatal dopamine D_2/3 receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment

References

• Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. 2013. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 170:609–615.
   Google Scholar
• Andreasen NC, Nopoulos P, Magnotta V, Pierson R, Ziebell S, Ho BC. 2011. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol Psychiatry. 70:672–679.
   Google Scholar
• Ansell BR, Dwyer DB, Wood SJ, Bora E, Brewer WJ, Proffitt TM, Velakoulis D, McGorry PD, Pantelis C. 2015. Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis. Psychol Med. 45(3):515–527.
   Google Scholar
• Bodnar M, Hovington CL, Buchy L, Malla AK, Joober R, Lepage M. 2014. Cortical thinning in temporo-parietal junction (TPJ) in non-affective first-episode of psychosis patients with persistent negative symptoms. PLoS One 9:e101372.
   Google Scholar
• Cahn W, Van Haren NE, Hulshoff Pol HE, Schnack HG, Caspers E, Laponder DA, Kahn RS. 2006. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry. 189:381–382.
   Google Scholar
• Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD. 2001. Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology. 40:847–855.
   Google Scholar
• Chua SE, Deng Y, Chen EY, Law CW, Chiu CP, Cheung C, Wong JC, Lienenkaëmper N, Cheung V, Suckling J, McAlonan GM. 2009. Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment. Psychol Med. 39:793–800.
   Google Scholar
• Coupe P, Manjon JV, Gedamu E, Arnold D, Robles M, Collins DL. 2010. Robust Rician noise estimation for MR images. Med Image Anal. 14:483–493.
   Google Scholar
• Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. 2005. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology. 30:1649–1661.
   Google Scholar
• Ebdrup BH, Glenthoj B, Rasmussen H, Aggernaes B, Langkilde AR, Paulson OB, Lublin H, Skimminge A, Baaré W. 2010. Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J Psychiatry Neurosci. 35:95–104.
   Google Scholar
• Ebdrup BH, Norbak H, Borgwardt S, Glenthoj B. 2013. Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. Curr Med Chem. 20:438–447.
   Google Scholar
• Ebdrup BH, Skimminge A, Rasmussen H, Aggernaes B, Oranje B, Lublin H, Baaré W, Glenthøj BY. 2011. Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. Int J Neuropsychopharmacol. 14:69–82.
   Google Scholar
• Fagerlund B, Mackeprang T, Gade A, Glenthøj BY. 2004. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr. 9:364–374.
   Google Scholar
• Fagerlund B, Pinborg LH, Mortensen EL, Friberg L, Baaré W, Gade A, Svarer C, Glenthøj BY. 2013. Relationship of frontal D(2/3) binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients. Int J Neuropsychopharmacol. 16:23–36.
   Google Scholar
• Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Montgomery AJ, Grasby PM, McGuire P. 2011. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry. 16:67–75.
   Google Scholar
• Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. 2013. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 37:1680–1691.
   Google Scholar
• Garver DL, Holcomb JA, Christensen JD. 2005. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry. 58:62–66.
   Google Scholar
• Girgis RR, Diwadkar VA, Nutche JJ, Sweeney JA, Keshavan MS, Hardan AY. 2006. Risperidone in first-episode psychosis: a longitudinal, exploratory voxel-based morphometric study. Schizophr Res. 82:89–94.
   Google Scholar
• Glenthoj A, Glenthoj BY, Mackeprang T, Pagsberg AK, Hemmingsen RP, Jernigan TL, Baaré WF. 2007. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res. 154:199–208.
   Google Scholar
• Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg LH, Friberg L, Baaré W, Hemmingsen R, Videbaek C. 2006. Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry. 60:621–629.
   Google Scholar
• Goghari VM, Smith GN, Honer WG, Kopala LC, Thornton AE, Su W, Macewan GW, Lang DJ. 2013. Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naive first-episode psychosis patients. Schizophr Res. 149:149–155.
   Google Scholar
• Haijma SV, Van HN, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. 2013. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull. 39:1129–1138.
   Google Scholar
• Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. 2011. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 68:128–137.
   Google Scholar
• Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH. 1993. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 54:257–268.
   Google Scholar
• Hyttel J, Larsen JJ, Christensen AV, Arnt J. 1985. Receptor-binding profiles of neuroleptics. Psychopharmacology Suppl. 2:9–18.
   Google Scholar
• Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, et al. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 27:1533–1539.
   Google Scholar
• Kambeitz J, Abi-Dargham A, Kapur S, Howes OD. 2014. Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry. 204:420–429.
   Google Scholar
• Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. 1995. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57:L103–L107.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276.
   Google Scholar
• Konopaske GT, Dorph-Petersen KA, Sweet RA, Pierri JN, Zhang W, Sampson AR, Lewis DA. 2008. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry. 63:759–765.
   Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 28:519–526.
   Google Scholar
• Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, Luthra SK, Osman S, Bloomfield PM, Jones T, Patsalos PN, et al. 1995. Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab. 15:152–165.
   Google Scholar
• Lee JS, Park HJ, Chun JW, Seok JH, Park IH, Park B, Kim JJ. 2011. Neuroanatomical correlates of trait anhedonia in patients with schizophrenia: a voxel-based morphometric study. Neurosci Lett. 489:110–114.
   Google Scholar
• Leucht S, Cipriani A, Geddes JR, Salanti G, Davis JM. 2013. Efficacy of antipsychotic drugs for schizophrenia - Authors' reply. Lancet. 382:1874–1875.
   Google Scholar
• Li J, Gu J, Wang B, Xie M, Huang L, Liu Y, Zhang L, Xue J, Guo F, Zhang L, Zhang L. 2014. Activation of dopamine D1 receptors regulates dendritic morphogenesis through Rac1 and RhoA in prefrontal cortex neurons. Mol Neurobiol. 51:1024–1037.
   Google Scholar
• Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, et al. 2005. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 62:361–370.
   Google Scholar
• Mackeprang T, Kristiansen KT, Glenthoj BY. 2002. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients. Biol Psychiatry. 52:863–873.
   Google Scholar
• Manjon JV, Coupe P, Buades A, Louis Collins D, Robles M. 2012. New methods for MRI denoising based on sparseness and self-similarity. Med Image Anal. 16:18–27.
   Google Scholar
• Molina V, Reig S, Sanz J, Palomo T, Benito C, Sánchez J, Sarramea F, Pascau J, Desco M. 2005. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr Res. 80:61–71.
   Google Scholar
• Norbak-Emig H, Ebdrup BH, Fagerlund B, Svarer C, Rasmussen H, Friberg L, Allerup PN, Rostrup E, Pinborg LH, Glenthøj BY. 2016. Frontal D2/3 receptor availability in schizophrenia patients before and after their first antipsychotic treatment: relation to cognitive functions and psychopathology. Int J Neuropsychopharmacol. 19(5):pyw006.
   Google Scholar
• Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. 1999. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 156:869–875.
   Google Scholar
• Parish CL, Finkelstein DI, Drago J, Borrelli E, Horne MK. 2001. The role of dopamine receptors in regulating the size of axonal arbors. J Neurosci. 21:5147–5157.
   Google Scholar
• Parish CL, Stanic D, Drago J, Borrelli E, Finkelstein DI, Horne MK. 2002. Effects of long-term treatment with dopamine receptor agonists and antagonists on terminal arbor size. Eur J Neurosci. 16:787–794.
   Google Scholar
• Pinborg LH, Videbaek C, Knudsen GM, Swahn CG, Halldin C, Friberg L, Paulson OB, Lassen NA. 2000. Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse. 36:322–329.
   Google Scholar
• Radua J, Borgwardt S, Crescini A, Mataix-Cols D, Meyer-Lindenberg A, McGuire PK, Fusar-Poli P. 2012. Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neurosci Biobehav Rev. 36:2325–2333.
   Google Scholar
• Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H. 2007. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 190:241–249.
   Google Scholar
• Roiz-Santianez R, Tordesillas-Gutierrez D, Foz O-G, Ayesa-Arriola R, Gutiérrez A, Tabarés-Seisdedos R, Vázquez-Barquero JL, Crespo-Facorro B. 2012. Effect of antipsychotic drugs on cortical thickness. A randomised controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Schizophr Res. 141:22–28.
   Google Scholar
• Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. 1996. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 124:57–73.
   Google Scholar
• Shenton ME, Dickey CC, Frumin M, McCarley RW. 2001. A review of MRI findings in schizophrenia. Schizophr Res. 49:1–52.
   Google Scholar
• Smith SM. 2002. Fast robust automated brain extraction. Hum Brain Mapp. 17:143–155.
   Google Scholar
• Torres US, Portela-Oliveira E, Borgwardt S, Busatto GF. 2013. Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis. BMC Psychiatry. 13:342.
   Google Scholar
• van Beijsterveldt LE, Geerts RJ, Leysen JE, Megens AA, Van den Eynde HM, Meuldermans WE, Heykants JJ. 1994. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl). 114:53–62.
   Google Scholar
• Van Haren NE, Cahn W, Hulshoff Pol HE, Kahn RS. 2013. Confounders of excessive brain volume loss in schizophrenia. Neurosci Biobehav Rev. 37:2418–2423.
   Google Scholar
• van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Brans R, Carati I, Rais M, Kahn RS. 2008. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry. 63:106–113.
   Google Scholar
• van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. 2003. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther. 25:1687–1699.
   Google Scholar
• Vernon AC, Crum WR, Lerch JP, Chege W, Natesan S, Modo M, Cooper JD, Williams SC, Kapur S. 2014. Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. Biol Psychiatry. 75:982–990.
   Google Scholar
• Vernon AC, Natesan S, Modo M, Kapur S. 2011. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and post-mortem confirmation. Biol Psychiatry. 69:936–944.
   Google Scholar
• Vita A, De Peri L, Deste G, Barlati S, Sacchetti E. 2015. The effect of antipsychotic treatment on cortical grey matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biol Psychiatry. 78:403–412.
   Google Scholar
• Vita A, De PL, Deste G, Sacchetti E. 2012. Progressive loss of cortical grey matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl Psychiatry. 2:e190.
   Google Scholar
• Weinberger DR, Radulescu E. 2016. Finding the elusive psychiatric ”lesion“ with 21st-century neuroanatomy: a note of caution. Am J Psychiatry. 173:27–33.
   Google Scholar
• Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N. 1990. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 47:589–593.
   Google Scholar
• Woods RP, Mazziotta JC, Cherry SR. 1993. MRI-PET registration with automated algorithm. J Comput Assist Tomogr. 17:536–546.
   Google Scholar
• Woodward ND, Zald DH, Ding Z, Riccardi P, Ansari MS, Baldwin RM, Cowan RL, Li R, Kessler RM. 2009. Cerebral morphology and dopamine D2/D3 receptor distribution in humans: a combined [18F]fallypride and voxel-based morphometry study. Neuroimage. 46:31–38.
   Google Scholar
• Zhang Y, Brady M, Smith S. 2001. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 20:45–57.
   Google Scholar
• Zipursky RB, Reilly TJ, Murray RM. 2013. The myth of schizophrenia as a progressive brain disease. Schizophr Bull. 39:1363–1372.
   Google Scholar